11,247 research outputs found
Efficacy of Anamorelin, a Novel Non-Peptide Ghrelin Analogue, in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) and Cachexia-Review and Expert Opinion
No full textCancer cachexia is a multilayered syndrome consisting of the interaction between tumor cells and the host, at times modulated by the pharmacologic treatments used for tumor control. Key cellular and soluble mediators, activated because of this interaction, induce metabolic and nutritional alterations. This results in mass and functional changes systemically, and can lead to increased morbidity and reduced length and quality of life. For most solid malignancies, a cure remains an unrealistic goal, and targeting the key mediators is ineffective because of their heterogeneity/redundancy. The most beneficial approach is to target underlying systemic mechanisms, an approach where the novel non-peptide ghrelin analogue anamorelin has the advantage of stimulating appetite and possibly food intake, as well as promoting anabolism and significant muscle mass gain. In the ROMANA studies, compared with placebo, anamorelin significantly increased lean body mass in non-small cell lung cancer (NSCLC) patients. Body composition analysis suggested that anamorelin is an active anabolic agent in patients with NSCLC, without the side effects of other anabolic drugs. Anamorelin also induced a significant and meaningful improvement of anorexia/cachexia symptoms. The ROMANA trials have provided unprecedented knowledge, highlighting the therapeutic effects of anamorelin as an initial, but significant, step toward directly managing cancer cachexia
sj-pdf-1-pmj-10.1177_02692163211040970 – Supplemental material for Performance status and trial site-level factors are associated with missing data in palliative care trials: An individual participant-level data analysis of 10 phase 3 trials
No full textSupplemental material, sj-pdf-1-pmj-10.1177_02692163211040970 for Performance status and trial site-level factors are associated with missing data in palliative care trials: An individual participant-level data analysis of 10 phase 3 trials by Jamilla A Hussain, Ian R White, Miriam J Johnson, Martin Bland and David C Currow in Palliative Medicine</p
Development of Indicators to Assess Quality of Care for Prostate Cancer
No full textAbstract not availableNupur Nag, Jeremy Millar, Ian D. Davis, Shaun Costello, James B. Duthie, Stephen Mark, Warick Delprado, David Smith, David Pryor, David Galvin, Frank Sullivan, Aine C. Murphy, David Roder, Hany Elsaleh, David Currow, Craig White, Marketa Skala, Kim L. Moretti, Tony Walker, Paolo De Ieso, Andrew Brooks, Peter Heathcote, Mark Frydenberg, Jeffery Thavaseelan, Sue M. Evan
Supplementary_Material_Interview_Schedule_-_Track_changes – Supplemental material for Nurses’ knowledge of law at the end of life and implications for practice: A qualitative study
No full textSupplemental material, Supplementary_Material_Interview_Schedule_-_Track_changes for Nurses’ knowledge of law at the end of life and implications for practice: A qualitative study by Lindy Willmott, Ben White, Patsy Yates, Geoffrey Mitchell, David C Currow, Katrin Gerber and Donella Piper in Palliative Medicine</p
sj-pdf-1-pmj-10.1177_02692163221122326 – Supplemental material for Paracentesis for cancer-related ascites in palliative care: An international, prospective cohort study
No full textSupplemental material, sj-pdf-1-pmj-10.1177_02692163221122326 for Paracentesis for cancer-related ascites in palliative care: An international, prospective cohort study by Davinia SE Seah, Andrew Wilcock, Sungwon Chang, Mariana S Sousa, Aynharan Sinnarajah, Cy Oun Teoh, Simon Allan, Richard Chye, Matthew Doogue, Jane Hunt, Meera Agar and David C Currow in Palliative Medicine</p
Palliation of nausea and vomiting
No full textNausea and vomiting (NV) are unpleasant symptoms reported as highly distressing by sufferers and have a significant impact on activities of daily living. The prevalence of nausea is 6-68% in people with advanced cancer, 17-48% in heart disease, 30-43% in renal disease, and 43-49% in people with AIDS and is not always associated with vomiting. Several multifactorial clinical syndromes can contribute to NV in patients with advanced illness. Two strategies have been proposed for the management of nausea and vomiting: the mechanistic and the empirical approach. Most of the evidence supporting the use of antiemetic drugs in palliative care has been extrapolated from trials of chemotherapy- and radiotherapy-induced NV. An ideal measurement tool for the assessment of NV and retching has yet to be developed. Inherent in the management of NV is to maximize treatment of those symptoms commonly associated with NV
sj-pdf-3-pmj-10.1177_02692163221122352 – Supplemental material for The range and suitability of outcome measures used in the assessment of palliative treatment for inoperable malignant bowel obstruction: A systematic review
No full textSupplemental material, sj-pdf-3-pmj-10.1177_02692163221122352 for The range and suitability of outcome measures used in the assessment of palliative treatment for inoperable malignant bowel obstruction: A systematic review by Alison Bravington, George Obita, Elin Baddeley, Miriam J Johnson, Fliss EM Murtagh, David C Currow, Elaine G Boland, Annmarie Nelson, Kathy Seddon, Alfred Oliver, Simon IR Noble and Jason W Boland in Palliative Medicine</p
sj-pdf-4-pmj-10.1177_02692163221122352 – Supplemental material for The range and suitability of outcome measures used in the assessment of palliative treatment for inoperable malignant bowel obstruction: A systematic review
No full textSupplemental material, sj-pdf-4-pmj-10.1177_02692163221122352 for The range and suitability of outcome measures used in the assessment of palliative treatment for inoperable malignant bowel obstruction: A systematic review by Alison Bravington, George Obita, Elin Baddeley, Miriam J Johnson, Fliss EM Murtagh, David C Currow, Elaine G Boland, Annmarie Nelson, Kathy Seddon, Alfred Oliver, Simon IR Noble and Jason W Boland in Palliative Medicine</p
sj-pdf-1-pmj-10.1177_02692163221122352 – Supplemental material for The range and suitability of outcome measures used in the assessment of palliative treatment for inoperable malignant bowel obstruction: A systematic review
No full textSupplemental material, sj-pdf-1-pmj-10.1177_02692163221122352 for The range and suitability of outcome measures used in the assessment of palliative treatment for inoperable malignant bowel obstruction: A systematic review by Alison Bravington, George Obita, Elin Baddeley, Miriam J Johnson, Fliss EM Murtagh, David C Currow, Elaine G Boland, Annmarie Nelson, Kathy Seddon, Alfred Oliver, Simon IR Noble and Jason W Boland in Palliative Medicine</p
sj-pdf-2-pmj-10.1177_02692163221122352 – Supplemental material for The range and suitability of outcome measures used in the assessment of palliative treatment for inoperable malignant bowel obstruction: A systematic review
No full textSupplemental material, sj-pdf-2-pmj-10.1177_02692163221122352 for The range and suitability of outcome measures used in the assessment of palliative treatment for inoperable malignant bowel obstruction: A systematic review by Alison Bravington, George Obita, Elin Baddeley, Miriam J Johnson, Fliss EM Murtagh, David C Currow, Elaine G Boland, Annmarie Nelson, Kathy Seddon, Alfred Oliver, Simon IR Noble and Jason W Boland in Palliative Medicine</p
- …
